Skip to main content

Growth Factors and Tyrosine Kinase Receptors

  • Chapter
  • First Online:
Textbook of Cell Signalling in Cancer
  • 3197 Accesses

Abstract

Signalling pathways originating from the interaction between growth factors (GF) and tyrosine kinase receptors (TKRs) are certainly the best known because of their leading role in oncogenesis. These pathways are multiple and will be studied in several chapters; the present chapter exclusively concerns GFs and TKRs, whereas Chaps. 2 and 3 will present two major signalling pathways downstream these interactions. We adopt here a definition of ‘growth factors’ restricted to those activating TKRs. Other classes of receptors will be studied in other chapters: receptors activating cytoplasmic tyrosine kinases (Chap. 4), serine/threonine kinase receptors (Chap. 5), etc.

More than 100 GF and 58 TKRs, distributed among 20 families, have been identified and a large part of them may play a role in oncogenesis. Activation of TKRs occurs according to a unique mechanism, involving dimerisation and autophosphorylation of the receptors, through their own tyrosine kinase activity, and constitutes the starting point of the signalling pathway. These dimeric associations of TKRs establish the link between GFs and cellular response; there exists a complex combinatorial pattern of these associations, which determines the type of action exerted on the cell receiving the signal. The number of possible combinations is high, which explains why the same signal may generate distinct consequences in the target cells: for instance, proliferation and differentiation may be induced by the same signal acting on different cells. Lastly, the signalling pathways downstream the GF–TKR interaction are multiple and depend upon the proteins expressed by the target cell, which is often referred to as ‘the cellular context’.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Further Reading

  • Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta. 2009;1795:37–52.

    CAS  PubMed  Google Scholar 

  • Appleman LJ. MET signaling pathway: a rational target for cancer therapy. J Clin Oncol. 2011;29:4837–8.

    Article  CAS  PubMed  Google Scholar 

  • Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8:235–53.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355–65.

    Article  CAS  PubMed  Google Scholar 

  • Blumenschein Jr GR, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol. 2012;30:3287–96.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Bose R, Zhang X. The ErbB kinase domain: structural perspectives into kinase activation and inhibition. Exp Cell Res. 2009;315:649–58.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, Light JE, Kolla V, Evans AE. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res. 2009;15:3244–50.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 2012;18:1855–62.

    Article  CAS  PubMed  Google Scholar 

  • Burgess AW, Cho HS, Eigenbrot C, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell. 2003;12:541–52.

    Article  CAS  PubMed  Google Scholar 

  • Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8:11–23.

    Article  CAS  PubMed  Google Scholar 

  • Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160–74.

    Article  CAS  PubMed  Google Scholar 

  • Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7:505–16.

    Article  CAS  PubMed  Google Scholar 

  • Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013;3:264–79.

    Article  CAS  PubMed  Google Scholar 

  • Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579–91.

    Article  CAS  PubMed  Google Scholar 

  • Ferguson KM. Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys. 2008;37:353–73.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2:795–803.

    Article  CAS  PubMed  Google Scholar 

  • Green JL, Kuntz SG, Sternberg PW. Ror receptor tyrosine kinases: orphans no more. Trends Cell Biol. 2008;18:536–44.

    Article  CAS  PubMed  Google Scholar 

  • Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004;4:361–70.

    Article  CAS  PubMed  Google Scholar 

  • Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer. 2013;13:685–700.

    Article  CAS  PubMed  Google Scholar 

  • Harari PM, Allen GW, Bonner JA. Biology of interactions: anti-epidermal growth factor receptor agents. J Clin Oncol. 2007;25:4057–65.

    Article  CAS  PubMed  Google Scholar 

  • Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer. 2008;8:880–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res. 2003;284:2–13.

    Article  CAS  PubMed  Google Scholar 

  • Heuckmann JM, Rauh D, Thomas RK. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer. J Clin Oncol. 2012;30:3417–20.

    Article  CAS  PubMed  Google Scholar 

  • Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res. 2003;284:99–110.

    Article  CAS  PubMed  Google Scholar 

  • Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol. 2004;44:195–217.

    Article  CAS  PubMed  Google Scholar 

  • Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–54.

    Article  CAS  PubMed  Google Scholar 

  • Jones RB, Gordus A, Krall JA, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature. 2006;439:168–74.

    Article  CAS  PubMed  Google Scholar 

  • Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003;284:31–53.

    Article  CAS  PubMed  Google Scholar 

  • Julien SG, Dubé N, Hardy S, Tremblay ML. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer. 2011;11:35–49.

    Article  CAS  PubMed  Google Scholar 

  • Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol. 2008;26:1742–51.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Leahy DJ. A molecular view of anti-ErbB monoclonal antibody therapy. Cancer Cell. 2008;13:291–3.

    Article  CAS  PubMed  Google Scholar 

  • Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117–34.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. 2008;100:35–83.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Mohebiany AN, Nikolaienko RM, Bouyain S, Harroch S. Receptor-type tyrosine phosphatase ligands: looking for the needle in the haystack. FEBS J. 2013;280:388–400.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Nikolaienko RM, Agyekum B, Bouyain S. Receptor protein tyrosine phosphatases and cancer: new insights from structural biology. Cell Adh Migr. 2012;6:356–64.

    Article  PubMed Central  PubMed  Google Scholar 

  • Nunes-Xavier CE, Martín-Pérez J, Elson A, Pulido R. Protein tyrosine phosphatases as novel targets in breast cancer therapy. Biochim Biophys Acta. 1836;2013:211–26.

    Google Scholar 

  • Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerisation in development and cancer. EMBO J. 2000;19:3159–67.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling – in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359–71.

    Article  CAS  PubMed  Google Scholar 

  • Ostman A, Hellberg C, Böhmer FD. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer. 2006;6:307–20.

    Article  PubMed  Google Scholar 

  • Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer. 2010;10:165–80.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Phay JE, Shah MH. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res. 2010;16:5936–41.

    Article  CAS  PubMed  Google Scholar 

  • Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8:915–28.

    Article  CAS  PubMed  Google Scholar 

  • Roskoski Jr R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74.

    Article  CAS  PubMed  Google Scholar 

  • Schlessinger J. Ligand-induced, receptor-mediated dimerisation and activation of EGF receptor. Cell. 2002;110:669–72.

    Article  CAS  PubMed  Google Scholar 

  • Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. J Cell Physiol. 2009;218:460–6.

    Article  CAS  PubMed  Google Scholar 

  • Scott LM, Lawrence HR, Sebti SM, Lawrence NJ, Wu J. Targeting protein tyrosine phosphatases for anticancer drug discovery. Curr Pharm Des. 2010;16:1843–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:15–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Sequist LV, Lynch TJ. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med. 2008;59:429–42.

    Article  CAS  PubMed  Google Scholar 

  • Sorkin A, Goh LK. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res. 2009;315:683–96.

    Article  CAS  PubMed  Google Scholar 

  • Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer. 2013;13:663–73.

    Article  CAS  PubMed  Google Scholar 

  • Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol. 2006;7:833–46.

    Article  CAS  PubMed  Google Scholar 

  • Tonks NK. Protein tyrosine phosphatases – from housekeeping enzymes to master regulators of signal transduction. FEBS J. 2013;280:346–78.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Verstraete K, Savvides SN. Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases. Nat Rev Cancer. 2012;12:753–66.

    Article  CAS  PubMed  Google Scholar 

  • Vlacich G, Coffey RJ. Resistance to EGFR-targeted therapy: a family affair. Cancer Cell. 2011;20:423–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Weiner HL, Zagzag D. Growth factor receptor tyrosine kinases: cell adhesion kinase family suggests a novel signaling mechanism in cancer. Cancer Invest. 2000;18:544–54.

    Article  CAS  PubMed  Google Scholar 

  • Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ. Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther. 2009;122:1–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res. 2008;6:1795–806.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127–37.

    Article  CAS  PubMed  Google Scholar 

  • Zha J, Lackner MR. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res. 2010;16:2512–7.

    Article  CAS  PubMed  Google Scholar 

  • Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell. 2006;125:1137–49.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Robert, J. (2015). Growth Factors and Tyrosine Kinase Receptors. In: Textbook of Cell Signalling in Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-14340-8_1

Download citation

Publish with us

Policies and ethics